JP5230407B2 - キノリン−カルボキサミド化合物の結晶形態物 - Google Patents

キノリン−カルボキサミド化合物の結晶形態物 Download PDF

Info

Publication number
JP5230407B2
JP5230407B2 JP2008505559A JP2008505559A JP5230407B2 JP 5230407 B2 JP5230407 B2 JP 5230407B2 JP 2008505559 A JP2008505559 A JP 2008505559A JP 2008505559 A JP2008505559 A JP 2008505559A JP 5230407 B2 JP5230407 B2 JP 5230407B2
Authority
JP
Japan
Prior art keywords
salt form
crystalline salt
crystalline
oxo
isopropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2008505559A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008535848A (ja
JP2008535848A5 (https=
Inventor
ポール アール． ファザリー，
エス． ディレック ターナー，
アダム ゴールドブルーム，
ロバート チャオ，
ダニエル ジェノブ，
Original Assignee
セラヴァンス， インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セラヴァンス， インコーポレーテッド filed Critical セラヴァンス， インコーポレーテッド
Publication of JP2008535848A publication Critical patent/JP2008535848A/ja
Publication of JP2008535848A5 publication Critical patent/JP2008535848A5/ja
Application granted granted Critical
Publication of JP5230407B2 publication Critical patent/JP5230407B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2008505559A 2005-04-06 2006-04-05 キノリン−カルボキサミド化合物の結晶形態物 Expired - Lifetime JP5230407B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66878005P 2005-04-06 2005-04-06
US60/668,780 2005-04-06
PCT/US2006/012978 WO2006108127A2 (en) 2005-04-06 2006-04-05 Crystalline form of a quinolinone-carboxamide compound

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012113464A Division JP2012153725A (ja) 2005-04-06 2012-05-17 キノリン−カルボキサミド化合物の結晶形態物

Publications (3)

Publication Number Publication Date
JP2008535848A JP2008535848A (ja) 2008-09-04
JP2008535848A5 JP2008535848A5 (https=) 2009-05-07
JP5230407B2 true JP5230407B2 (ja) 2013-07-10

Family

ID=37074104

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008505559A Expired - Lifetime JP5230407B2 (ja) 2005-04-06 2006-04-05 キノリン−カルボキサミド化合物の結晶形態物
JP2012113464A Withdrawn JP2012153725A (ja) 2005-04-06 2012-05-17 キノリン−カルボキサミド化合物の結晶形態物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012113464A Withdrawn JP2012153725A (ja) 2005-04-06 2012-05-17 キノリン−カルボキサミド化合物の結晶形態物

Country Status (29)

Country Link
US (4) US7728004B2 (https=)
EP (1) EP1874766B1 (https=)
JP (2) JP5230407B2 (https=)
KR (1) KR101322873B1 (https=)
CN (1) CN101151264B (https=)
AR (2) AR053208A1 (https=)
AT (1) ATE479682T1 (https=)
AU (1) AU2006232129B2 (https=)
BR (1) BRPI0610657A2 (https=)
CA (1) CA2603654C (https=)
CY (1) CY1111275T1 (https=)
DE (1) DE602006016586D1 (https=)
DK (1) DK1874766T3 (https=)
EA (1) EA012115B1 (https=)
ES (1) ES2350495T3 (https=)
HR (1) HRP20100629T1 (https=)
IL (1) IL186023A (https=)
MA (1) MA29403B1 (https=)
MX (1) MX2007012438A (https=)
MY (1) MY151075A (https=)
NO (1) NO339699B1 (https=)
NZ (1) NZ561900A (https=)
PE (1) PE20061310A1 (https=)
PL (1) PL1874766T3 (https=)
PT (1) PT1874766E (https=)
SI (1) SI1874766T1 (https=)
TW (1) TWI377206B (https=)
WO (1) WO2006108127A2 (https=)
ZA (1) ZA200708071B (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7063671B2 (en) * 2002-06-21 2006-06-20 Boston Scientific Scimed, Inc. Electronically activated capture device
US7728006B2 (en) * 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
TWI351282B (en) * 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
ATE441646T1 (de) * 2004-11-05 2009-09-15 Theravance Inc 5-ht4-rezeptoragonistenverbindungen
EP1807423B1 (en) 2004-11-05 2009-05-20 Theravance, Inc. Quinolinone-carboxamide compounds
TWI377206B (en) * 2005-04-06 2012-11-21 Theravance Inc Crystalline form of a quinolinone-carboxamide compound
EP1945632B1 (en) 2005-11-08 2013-09-18 Vertex Pharmaceuticals Incorporated Heterocyclic modulators of atp-binding cassette transporters
AU2008254999A1 (en) * 2007-05-17 2008-11-27 Theravance, Inc. Prokinetic agent for bowel preparation
CH698729B1 (de) * 2007-05-30 2009-10-15 Cerbios Pharma Sa Stabile, kristalline (6S)-N(5)-Methyl-5, 6,7,8-tetrahydrofolsäure.
SI2225230T1 (sl) * 2007-12-07 2017-03-31 Vertex Pharmaceuticals Incorporated Trdne oblike 3-(6-(1-2,2-difluorobenzo(d)(1,3)dioxol-5-il)ciklopropan- karboksamido)-3-metilpiridin-2-il) benzojske kisline
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
CA2758321A1 (en) 2009-04-13 2010-10-21 Theravance, Inc. 5-ht4 receptor agonist compounds for treatment of cognitive disorders
JP2013518085A (ja) 2010-02-01 2013-05-20 ノバルティス アーゲー ＣＲＦ−１受容体アンタゴニストとしてのピラゾロ［５，１ｂ］オキサゾール誘導体
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
JP5748777B2 (ja) 2010-02-02 2015-07-15 ノバルティス アーゲー Ｃｒｆ受容体アンタゴニストとしてのシクロヘキシルアミド誘導体
HRP20211752T1 (hr) 2010-04-07 2022-02-18 Vertex Pharmaceuticals Incorporated Farmaceutski pripravci 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline i njihova primjena
WO2013112804A1 (en) 2012-01-25 2013-08-01 Vertex Pharmaceuticals Incorporated Formulations of 3-(6-(1-(2.2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
JP6963896B2 (ja) 2013-11-12 2021-11-10 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated Ｃｆｔｒ媒介性疾患の処置のための医薬組成物を調製する方法
BR112020000482A2 (pt) 2017-07-31 2020-07-21 Theravance Biopharma R&D Ip, Llc métodos de tratamento de sintomas de gastroparesia usando velusetrag
US10570127B1 (en) 2018-11-05 2020-02-25 Renexxion, Llc Material and methods for the treatment of gastro-intestinal disorders
EP4590303A1 (en) * 2022-09-20 2025-07-30 Alfasigma S.p.A. Velusetrag for use in the treatment of chronic intestinal pseudo-obstruction (cipo)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3122671B2 (ja) * 1990-05-23 2001-01-09 協和醗酵工業株式会社 複素環式化合物
DE69113284T2 (de) * 1990-12-28 1996-02-22 Kyowa Hakko Kogyo Co., Ltd., Tokio/Tokyo Chinolinderivat.
EP0670319A4 (en) * 1992-11-20 1996-01-17 Thaisho Pharmaceutical Co Ltd HETEROCYCLIC COMPOUNDS.
JP3829879B2 (ja) * 1994-05-18 2006-10-04 大正製薬株式会社 キノリンカルボン酸誘導体
TW402591B (en) * 1997-07-11 2000-08-21 Janssen Pharmaceutica Nv Monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
US7105195B2 (en) * 2003-07-25 2006-09-12 General Mills, Inc. Reduced trans fat product
DE602004026095D1 (de) 2003-11-24 2010-04-29 Pfizer Chinoloncarbonsäureverbindungen mit 5-ht4-rezeptoragonistischer wirkung
TWI351282B (en) * 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
US7728006B2 (en) * 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
ATE441646T1 (de) * 2004-11-05 2009-09-15 Theravance Inc 5-ht4-rezeptoragonistenverbindungen
EP1807423B1 (en) * 2004-11-05 2009-05-20 Theravance, Inc. Quinolinone-carboxamide compounds
WO2006088988A1 (en) 2005-02-17 2006-08-24 Theravance, Inc. Crystalline form of an indazole-carboxamide compound
NZ560828A (en) * 2005-03-02 2011-01-28 Theravance Inc Quinolinone compounds as 5-HT4 receptor agonists
TWI377206B (en) * 2005-04-06 2012-11-21 Theravance Inc Crystalline form of a quinolinone-carboxamide compound

Also Published As

Publication number Publication date
KR101322873B1 (ko) 2013-10-30
EA200702161A1 (ru) 2008-04-28
CN101151264A (zh) 2008-03-26
US7728004B2 (en) 2010-06-01
EP1874766A2 (en) 2008-01-09
DE602006016586D1 (de) 2010-10-14
WO2006108127A2 (en) 2006-10-12
HK1110866A1 (en) 2008-07-25
TW200643020A (en) 2006-12-16
MY151075A (en) 2014-03-31
US9126994B2 (en) 2015-09-08
US20160095849A1 (en) 2016-04-07
PT1874766E (pt) 2010-11-30
ATE479682T1 (de) 2010-09-15
EA012115B1 (ru) 2009-08-28
KR20070116988A (ko) 2007-12-11
US20060229332A1 (en) 2006-10-12
DK1874766T3 (da) 2010-12-06
EP1874766B1 (en) 2010-09-01
TWI377206B (en) 2012-11-21
NO20075574L (no) 2007-11-02
PL1874766T3 (pl) 2011-02-28
JP2008535848A (ja) 2008-09-04
AR053208A1 (es) 2007-04-25
NZ561900A (en) 2010-12-24
CN101151264B (zh) 2011-07-06
PE20061310A1 (es) 2007-01-23
WO2006108127A3 (en) 2007-01-04
AU2006232129A1 (en) 2006-10-12
AU2006232129B2 (en) 2012-07-12
ZA200708071B (en) 2008-10-29
US8658671B2 (en) 2014-02-25
US9402840B2 (en) 2016-08-02
SI1874766T1 (sl) 2010-12-31
MX2007012438A (es) 2007-12-05
IL186023A0 (en) 2008-01-20
US20140256769A1 (en) 2014-09-11
MA29403B1 (fr) 2008-04-01
BRPI0610657A2 (pt) 2010-07-13
ES2350495T3 (es) 2011-01-24
CY1111275T1 (el) 2015-08-05
AR110019A2 (es) 2019-02-13
CA2603654A1 (en) 2006-10-12
JP2012153725A (ja) 2012-08-16
HRP20100629T1 (hr) 2010-12-31
US20100197728A1 (en) 2010-08-05
NO339699B1 (no) 2017-01-23
IL186023A (en) 2011-09-27
CA2603654C (en) 2014-05-27

Similar Documents

Publication Publication Date Title
JP2012153725A (ja) キノリン−カルボキサミド化合物の結晶形態物
JP4944012B2 (ja) ５−ｈｔ４レセプターアゴニストとしてのキノリノン−カルボキサミド化合物
JP2007523175A (ja) ５−ｈｔ４レセプターアゴニストとしてのインダゾール−カルボキシアミド化合物
EP1807423B1 (en) Quinolinone-carboxamide compounds
US20060183901A1 (en) Crystalline form of an indazole-carboxamide compound
US7728006B2 (en) Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
US20100285519A1 (en) Quinolinone-carboxamide compounds as 5-ht4 receptor agonists
HK1110866B (en) Crystalline form of a quinolinone-carboxamide compound
HK1099019B (en) Quinolinone-carboxamide compounds as 5-ht4 receptor agonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090317

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090317

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120517

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120703

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120914

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130315

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130319

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20160329

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 5230407

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250